Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products... Show more
The 10-day moving average for CPIX crossed bullishly above the 50-day moving average on September 02, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where CPIX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CPIX just turned positive on August 20, 2025. Looking at past instances where CPIX's MACD turned positive, the stock continued to rise in of 58 cases over the following month. The odds of a continued upward trend are .
CPIX moved above its 50-day moving average on September 09, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CPIX advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Momentum Indicator moved below the 0 level on September 12, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CPIX as a result. In of 120 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 50-day moving average for CPIX moved below the 200-day moving average on August 20, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
CPIX broke above its upper Bollinger Band on September 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CPIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CPIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.839) is normal, around the industry mean (17.281). P/E Ratio (0.000) is within average values for comparable stocks, (74.632). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.886). CPIX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.030). P/S Ratio (1.197) is also within normal values, averaging (46.794).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a developer of branded prescription products
Industry PharmaceuticalsGeneric
A.I.dvisor tells us that CPIX and QNTM have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CPIX and QNTM's prices will move in lockstep.
Ticker / NAME | Correlation To CPIX | 1D Price Change % | ||
---|---|---|---|---|
CPIX | 100% | +0.29% | ||
QNTM - CPIX | 26% Poorly correlated | +7.55% | ||
LFCR - CPIX | 22% Poorly correlated | -3.22% | ||
ACB - CPIX | 22% Poorly correlated | -1.22% | ||
SHOT - CPIX | 22% Poorly correlated | -1.39% | ||
ELAN - CPIX | 21% Poorly correlated | -1.33% | ||
More |
Ticker / NAME | Correlation To CPIX | 1D Price Change % |
---|---|---|
CPIX | 100% | +0.29% |
Pharmaceuticals: Generic industry (221 stocks) | 9% Poorly correlated | -0.31% |